TEL AVIV, Israel, July 5, 2018 /PRNewswire/ --
Cellect Biotechnology Ltd. (Nasdaq:
APOP), a developer of a novel stem cell production technology,
announced that it has signed a collaboration and material transfer
agreement with the denovoMATRIX group of the Technische Universität
Dresden (TU Dresden).
TU Dresden and its Center for Regenerative Therapies Dresden
(CRTD), is one of the leading centers for stem cell research in
Germany.
The two entities believe that the combination of both
proprietary technologies may result in significant enhancement of
the overall stem cell selection and expansion processes.
According to the agreement, the team of denovoMATRIX employed by
TU Dresden will conduct examinations into the tentative synergy
between Cellect's ApoGraft™ and the denovoMAtrix technology for the
purpose of evaluating collaborative development of products for
regenerative medicine. To that end, a denovoMATRIX scientist will
conduct a line of experiments in Cellect's R&D facility in
Israel.
In the event of successful completion of the evaluation stage,
both sides agreed to negotiate in good faith a potential mutual
development agreement, for the development of a stem cell related
product. Cellect will have the sole discretion on determining
the level of success of the evaluation stage.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a
breakthrough technology for the selection of stem cells from any
given tissue that aims to improve a variety of stem cell-based
therapies.
The Company's technology is expected to provide research,
hospitals and pharma companies with the tools to rapidly isolate
stem cells in quantity and quality allowing stem cell-based
treatments and procedures in a wide variety of applications in
regenerative medicine. The Company's current clinical trial is
aimed at bone marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss the Company's belief regarding the results of any
future collaboration with denovoMATRIX. These forward-looking
statements and their implications are based on the current
expectations of the management of the Company only and are subject
to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the
forward-looking statements. In addition, historical results or
conclusions from scientific research and clinical studies do not
guarantee that future results would suggest similar conclusions or
that historical results referred to herein would be interpreted
similarly in light of additional research or otherwise. The
following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: the Company's history of losses and needs for
additional capital to fund its operations and its inability to
obtain additional capital on acceptable terms, or at all; the
Company's ability to continue as a going concern; uncertainties of
cash flows and inability to meet working capital needs; the
Company's ability to obtain regulatory approvals; the Company's
ability to obtain favorable pre-clinical and clinical trial
results; the Company's technology may not be validated and its
methods may not be accepted by the scientific community;
difficulties enrolling patients in the Company's clinical trials;
the ability to timely source adequate supply of FasL; risks
resulting from unforeseen side effects; the Company's ability to
establish and maintain strategic partnerships and other corporate
collaborations; the scope of protection the Company is able to
establish and maintain for intellectual property rights and its
ability to operate its business without infringing the intellectual
property rights of others; competitive companies, technologies and
the Company's industry; unforeseen scientific difficulties may
develop with the Company's technology; and the Company's ability to
retain or attract key employees whose knowledge is essential to the
development of its products.. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in the Company's Annual Report on Form
20-F for the fiscal year ended December 31,
2017 filed with the U.S. Securities and Exchange Commission
("SEC"), which is available on the SEC's website,
http://www.sec.gov, and in the Company's periodic filings with the
SEC.
Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial
Officer
http://www.cellect.co
+ 972-9-974-1444
SOURCE Cellect Biotechnology Ltd.